【www.zhangdahai.com--思想汇报】
摘要: 目的:检测环氧化酶-2(COX-2)在膀胱癌组织中的表达,探讨COX-2表达与膀胱癌临 床病理的关系。方法:采用免疫组化方法检测56例膀胱癌组织中COX-2的表达。结果:膀胱癌 组织中COX-2的阳性表达率为57.1%。COX-2的表达与肿瘤的病理分级和临床分期相关。结 论:COX-2的异常表达可能在膀胱移行细胞癌的发生发展中起一定的作用。
关键词:膀胱移行细胞癌;环氧化酶-2;免疫组化
中图分类号: R737.14 文献标识码: A 文章编号: 1008-2409(2009)05-0805-03
Expression of cyclooxygenase-2 in human transitional cell carcinoma of t he bladder/LU Hao-yuan, BAI Xian-zhong∥The Affiliated Tumor Hospital of Guang xi Medical University, Nanning 530027, China
Abstract:Objective:To study the expression of cyclooxygenase-2(COX-2) in human transiti onal cel l carcinoma of the bladder(BTCC)and their relationship with clinical pathologic al characteristics. Methods: S-P immunohistochemistry staining was performed t o e valuate the positivity of COX-2 in fifty-six cases of transitional cell carcin om a of the bladder and 10 cases of normal bladder mucosa. Results: The positive e xp ression of COX-2 were 57.1%(32/56), the expression of COX-2 was related tocl inic stage and the tumor grade(PTMplus广谱试剂盒(KIT-9901);用EDTA修复法修复 抗原;DAB法显色。采用已经研究证实为COX-2蛋白阳性表达的肺癌标本作为阳性对照,以P BS替代一抗为空白对照。
1.3 结果判断
参照文献报道[1],显微镜下观察细胞染色情况,COX-2阳性细胞的标志为细胞浆 内或胞膜 上呈棕黄色,分4个级别。分级标准为∶-,细胞无着色;+,细胞胞浆内微弱且弥漫染色 (可以包括90%的细胞胞浆内强染色;-,判定为阴性表达,+~�为阳性表达。
1.4 统计学分析
实验结果采用SPSS 10.0进行统计处理,α值取0.05作为显著性标准。
2 结果
2.1 COX-2在膀胱癌细胞的表达
COX-2阳性表达产物呈黄色颗粒状,表达较强时呈棕黄色,定位于癌细胞浆中。COX- 2在膀胱癌细胞中阳性表达率为57.14%(32/56),其中弱阳性11例,中等阳性15例,强阳性 6例,但在正常膀胱细胞中为阴性表达,见表1。
COX-2的阳性表达与膀胱移行细胞癌的生物学行为密切相关,与膀胱移行细胞癌病理分级､ 临床分期密切相关,差异有统计学意义(分别为P
参考文献:
[1] RISTIMAKI A�,NIEMINEN O,SAUKKONEN K,et al.Expression of cyclooxygenase-2 i n human transitional cell carcinoma of the urinary bladder[J]. Am J Pathol,2 001,158(3):849-853.
[2] FAMAEY J P�.In vitro and in vivo pharmacological evidence ofselective cycloox ygenase-2 inhibition by nimesulide an overview[J]. Inflamm Res,1997,46(11 ):437-446.
[3] DANNENBERG A J�,ALTORKI N K,BOYLE J O,et al.Cyclooxygenase-2:a pharmacologic al target for the prevention of cancer[J]. Lancet Oncol,2001,2(9):544-551 .
[4] KIM M H�,SEO S S,SORG Y S,et al.Expression of cyclooxygenase-1 and-2 associa ted with expression of VEGF in primary cervical cancer and at metastatic lymph n odes[J]. Gynecol Oncol,2003,90(1):83-90.
[5] HOWE L R�,DANNENBERG A T.A role for cyclooxygenase-2 inhibi tors in the prevent ion and treatment of cancer[J]. Semin Oncol,2002,29(3 Suppl-11):111-119 .
[6] WULFING C�,ELTZE E,VON STRUENSEE D,et al.Cyclooxygenase-2 expression in bl adder cancer:tumor-biological and clinical implications[J]. Aktuelle Urol, 2004,35(4):331-338.
[7] RACK,IKTRISAN C�,STEEKE V,et al.Differential activity of a spirin,ketoprofe n and sulindac as cancer chemopreventive agents in the mouse urinary bladder[J ]. Carcinogenesis,1996,17(5):1435-1438.
[8] YOSHIMURA R�,SANO H,MITSUHASHI M,et al.Expression of cyclooxy genase-2 in patient with bladder cancer[J]. J Lirol,2001,165(5):1468-147 2.
(收稿日期: 2009-08-02)
[责任编辑 王慧瑾 邓德灵]
